Management of Pancreatic Neuroendocrine Tumors

被引:20
作者
Dickson, Paxton V. [1 ]
Behrman, Stephen W. [1 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Surg, Div Surg Oncol, Memphis, TN 38163 USA
关键词
Pancreatic neuroendocrine tumors; Surgery; Metastatic neuroendocrine tumors; Chemotherapy; Targeted therapy; HEPATIC ARTERIAL CHEMOEMBOLIZATION; LONG-TERM SURVIVAL; ENDOCRINE TUMORS; SURGICAL-TREATMENT; LIVER METASTASES; CHROMOGRANIN-A; PHASE-II; RADIOFREQUENCY ABLATION; CONSENSUS GUIDELINES; LOW-GRADE;
D O I
10.1016/j.suc.2013.02.001
中图分类号
R61 [外科手术学];
学科分类号
摘要
Pancreatic neuroendocrine tumors account for 1% to 2% of pancreatic neoplasms and may occur sporadically or as part of a hereditary syndrome. Patients may present with symptoms related to hormone secretion by functional tumors or to locally advanced or metastatic nonfunctional tumors. Asymptomatic pancreatic neuroendocrine tumors are increasingly detected incidentally during abdominal imaging performed for other reasons. The management of localized pancreatic neuroendocrine tumors is surgical resection. Hepatic metastases are common and their management involves a variety of liver-directed therapies, which should be tailored according to extent of disease, symptoms, presence of extrahepatic metastases, and patient performance status.
引用
收藏
页码:675 / +
页数:18
相关论文
共 101 条
[1]  
Anderson MA, 2000, AM J GASTROENTEROL, V95, P2271
[2]  
[Anonymous], 2010, AJCC CANC STAGING MA
[3]   Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors [J].
Bilimoria, Karl Y. ;
Bentrem, David J. ;
Merkow, Ryan P. ;
Tomlinson, James S. ;
Stewart, Andrew K. ;
Ko, Clifford Y. ;
Talamonti, Mark S. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 205 (04) :558-563
[4]   Hospital volume and surgical mortality in the United States. [J].
Birkmeyer, JD ;
Siewers, AE ;
Finlayson, EVA ;
Stukel, TA ;
Lucas, FL ;
Batista, I ;
Welch, HG ;
Wennberg, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15) :1128-1137
[5]   Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma [J].
Butturini, G. ;
Bettini, R. ;
Missiaglia, E. ;
Mantovani, W. ;
Dalai, I. ;
Capelli, P. ;
Ferdeghini, M. ;
Pederzoli, P. ;
Scarpa, A. ;
Falconi, M. .
ENDOCRINE-RELATED CANCER, 2006, 13 (04) :1213-1221
[6]   Chromogranin A: Is it a useful marker of neuroendocrine tumors? [J].
Campana, Davide ;
Nori, Francesca ;
Piscitelli, Lidya ;
Morselli-Labate, Antonio Maria ;
Pezzilli, Raffaele ;
Corinaldesi, Roberto ;
Tomassetti, Paola .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1967-1973
[7]  
Capelli P, 2009, ARCH PATHOL LAB MED, V133, P350, DOI 10.1043/1543-2165-133.3.350
[8]   Hepatic neuroendocrine metastases: Does intervention alter outcomes? [J].
Chamberlain, RS ;
Canes, D ;
Brown, KT ;
Saltz, L ;
Jarnagin, W ;
Fong, YM ;
Blumgart, LH .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000, 190 (04) :432-445
[9]   Liver transplantation for symptomatic liver metastases of neuroendocrine tumours [J].
Chan, G. ;
Kocha, W. ;
Reid, R. ;
Taqi, A. ;
Wall, W. ;
Quan, D. .
CURRENT ONCOLOGY, 2012, 19 (04) :217-221
[10]   Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors [J].
Chan, Jennifer A. ;
Stuart, Keith ;
Earle, Craig C. ;
Clark, Jeffrey W. ;
Bhargava, Pankaj ;
Miksad, Rebecca ;
Blaszkowsky, Lawrence ;
Enzinger, Peter C. ;
Meyerhardt, Jeffrey A. ;
Zheng, Hui ;
Fuchs, Charles S. ;
Kulke, Matthew H. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) :2963-2968